Not a good buy right now for an impatient buyer: the chart is extended but momentum is weakening (MACD rolling over) while valuation concerns dominate recent commentary.
Options positioning is cautious-to-bearish near current levels (put volume > call volume), suggesting traders are hedging/expecting choppiness rather than chasing upside.
Fundamentals last reported quarter were weak on the top line (revenue down YoY) and profitability swung negative, increasing the risk of disappointment into the next earnings (2026-02-13 pre-market).
Momentum: MACD histogram -0.0683 and negatively expanding = near-term momentum cooling / risk of pullback despite bullish longer-term trend.
RSI(6) 57.39 = neutral (not overbought, but not a clear fresh breakout signal).
Pattern-based forward look (provided): 80% chance of +0.83% next day, +3.59% next week, +4.25% next month—positive bias, but not strong enough to override weakening MACD at highs.
Options Data
Neutral
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Open interest: Calls 220,600 vs Puts 225,820; OI put/call 1.02 = slightly more put positioning (cautious).
Volume: Put/call volume ratio 1.27 with put volume 21,998 vs call volume 17,360 = near-term bearish/hedging tone.
Activity elevated: today’s option volume 39,358 (~126% of 30-day avg) = heightened positioning into a catalyst window.
Volatility: IV 30d 55.76 vs historical vol 76.9; IV percentile 85.6 (rich) = options priced for big moves; tends to appear when uncertainty is high.
Technical Summary
Sell
5
Buy
8
Positive Catalysts
Sector tailwind: news flow argues uranium is in a long-term bull phase with supply-demand imbalance and potential multi-year price upside.
Policy catalyst: U.S. DOE initiative to build nuclear fuel supply chain (headline figure: potential $50B private investment) supports domestic nuclear/uranium ecosystem.
Strategic positioning: Cameco highlighted as a major uranium producer with leverage to rising nuclear demand and its Westinghouse stake.
Street generally constructive: multiple firms reiterate Buy/Outperform with raised targets into late 2025/early 2026.
Neutral/Negative Catalysts
on 2026-02-13 pre-market—stock could gap either direction; recent quarter showed revenue/profit volatility.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 614.6M, -14.72% YoY (contraction).
Net income: -0.141M, down -101.90% YoY (swing to slight loss).
EPS: 0, down -100% YoY.
Bright spot: Gross margin 27.7%, +16.83% YoY, indicating better unit economics even as reported revenue/profits weakened.
Takeaway: improving margin but inconsistent earnings power recently—adds risk when the stock is priced for strong outcomes.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: broadly bullish bias with multiple Buy/Outperform ratings and several price-target raises across late 2025 into early 2026.
Notable actions: Bernstein (Outperform, PT to $101), GLJ (Buy, PT to $99.74), RBC (Outperform, slight PT cut), TD (Buy, PT raise), National Bank (Outperform, PT raise), UBS initiated Neutral (balanced risk/reward after sharp gains).
BofA entries show mixed adjustments around the same date (refreshing forecasts), but the stance remains Buy overall.
Wall Street “cons” view: premium valuation after a big run and near-term execution/timing noise in results.
Wall Street analysts forecast CCJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCJ is 105.67 USD with a low forecast of 71.8 USD and a high forecast of 118.78 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast CCJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCJ is 105.67 USD with a low forecast of 71.8 USD and a high forecast of 118.78 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 109.280
Low
71.8
Averages
105.67
High
118.78
Current: 109.280
Low
71.8
Averages
105.67
High
118.78
Goldman Sachs
Buy
maintain
$115 -> $131
AI Analysis
2026-02-04
New
Reason
Goldman Sachs
Price Target
$115 -> $131
AI Analysis
2026-02-04
New
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Cameco to $131 from $115 and keeps a Buy rating on the shares.
Bernstein
Outperform
maintain
$100 -> $101
2026-01-07
Reason
Bernstein
Price Target
$100 -> $101
2026-01-07
maintain
Outperform
Reason
Bernstein raised the firm's price target on Cameco to $101 from $100 and keeps an Outperform rating on the shares. The firm cites higher uranium price deck for the price target change.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CCJ
